share……………...3,450,000$60.24$207,828,000$25,875(1)Includes 450,000 shares of common stock that the underwriters have the option to purchase.(2)Estimated solely for the purposes of calculating the amount of the registration fee in accordance with Rule 457(c) under the Securities Act of 1933, as amended, and is based on the average of the high and low sales
statements and related notes incorporated by reference into this prospectus.Year EndedDecember 31,Six Months EndedJune 30,(in thousands, except per share data)20142015201620162017(unaudited)Consolidated Statements of Operations Data:Collaboration revenue$15,838$17,571$16,684$10,716$7,000Operating expenses:Research and development8,61417,30415,4197,12115,140General and administrative2,3543,5894,2902,3714,403Total operating expenses10,96820,89319,7099,49219,543Income (loss) from operations4,870(3,322)(3,025)1,224(12,543)Other income (expense), netInterest expense(1,281)(460)(458)(231)(867)Change in fair value of liability for preferred stock warrants(59)(1,277)(756)382(1,366)Other income (expense), net2(207)(20)59657Total other income (expense), net(1,338)(1,944)(1,234)210(1,576)Income (loss) before income taxes3,532(5,266)(4,259)1,434(14,119)Provision for income taxes—(139)———Net income (loss)3,532(5,405)(4,259)1,434(14,119)Net income (loss) attributed to participating securities(3,300)——(1,434)—Net income (loss) attributed to common stockholders232(5,405)(4,259)—(14,119)Unrealized loss on available for sale securities————(59)Other comprehensive loss————(59)Comprehensive income (loss)$232$(5,405)$(4,259)$—$(14,178)Net income (loss) per common share:(1)Basic and diluted$0.09$(2.12)$(1.62)$—$(0.79)13Table of ContentsYear EndedDecember 31,Six Months EndedJune 30,(in thousands, except per share data)20142015201620162017(unaudited)Weighted-average number of shares outstanding:(1)Basic2,4812,5512,6372,63217,797Diluted2,4812,5512,6373,49717,797(1)See Note 2 to our audited consolidated financial statements incorporated by reference in this prospectus for an explanation of the method used to calculate basic and diluted net income (loss) per common share and
the weighted-average number of shares used in the computation of the per share amounts.As ofJune 30, 2017(unaudited)(in thousands)ActualAsAdjusted(1)(2)Consolidated Balance Sheet Data:Cash, cash equivalents, and short-term investments$106,359$306,415Total assets130,409330,465Notes payable, net of current portion10,98710,987Total stockholders’ equity109,175309,231(1)The as adjusted balance sheet data give effect to the sale of 3,000,000 shares of common stock by us in this offering, based on an assumed public offering price of $70.41 per share, the last reported sale price of
to strategic products in key commercial markets;•our ability to obtain funding for our operations, including funding necessary to complete further development and commercialization of our product candidates;•the timing of and our ability to obtain and maintain regulatory approvals for ANB020 and ANB019 and our other product candidates;•our ability to develop our product candidates;•the rate and degree of market acceptance and clinical utility of any approved product candidates;•the size and growth potential of the markets for any approved product candidates, and our ability to serve those markets;•our commercialization, marketing and manufacturing capabilities and strategy;•our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates;•regulatory developments in the United States, the United Kingdom, Australia and other foreign countries;•the success of competing therapies that are or may become available;•our ability to attract and retain key scientific or management personnel;•our use of the net proceeds from this offering;•our ability to identify additional products or product candidates with significant commercial potential that are consistent with our commercial objectives; and•our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.16Table of ContentsThese forward-looking statements are subject to a number of risks, uncertainties and assumptions,
paying cash dividends without the consent of Silicon Valley Bank.20Table of ContentsCAPITALIZATIONThe following table sets forth our cash, cash equivalents and short-term investments and capitalization as of June 30, 2017 on:•an actual basis; and•an as adjusted basis, giving effect to the sale of 3,000,000 shares of common stock by us in this offering, based on an assumed public offering price of $70.41 October 10, 2017, after deducting the
Operations” and our audited and unaudited consolidated financial statements and related notes incorporated by reference into this prospectus.As of June 30, 2017(unaudited)(in thousands, except share and par value data)ActualAs Adjusted(1)Cash, cash equivalents and short-term investments$106,359$306,415Notes payable, net of current portion$10,987$10,987Deferred rent, net of current portion168168Stockholders’ equity:Preferred Stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding,
share, the last reported sale price of our common stock on The NASDAQ Global Select Market on October 10, 2017, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, our net
description, you should refer to our restated certificate of incorporation and restated bylaws, which are included as exhibits to the registration statement of which this prospectus forms a part, and to the applicable provisions of Delaware law.As of June 30, 2017, there were 20,289,907 shares of our common stock issued, held by approximately 95 stockholders of record, and
dividends paid to certain foreign financial institutions ornon-financialforeign entities.Sale of Common StockSubject to the discussions below regarding Backup Withholding and Information Reporting and the Foreign Account Tax Compliance Act,non-U.S.holders will generally not be subject to U.S. federal income tax on any gains realized on the sale, exchange or other disposition of our common stock unless:•the gain (i) is effectively connected with the conduct by thenon-U.S.holder of a U.S. trade or business and (ii) if required by an applicable income tax treaty between
Financial Services and Markets Act 2000 (FSMA) received by it in connection with the issue or sale of the securities in circumstances in which Section 21 of the FSMA does not apply to us; and(b)it has complied with, and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to the securities in, from or otherwise involving the United Kingdom.Notice to Canadian ResidentsResale RestrictionsThe distribution of shares of common stock offered hereby in Canada is being made only in the provinces of Ontario, Quebec, Alberta and British